Tag: sarcopenia
Biophytis: The United States authorizes Biophytis to launch a final phase of clinical trials in sarcopenia
(BFM Bourse) – The biopharmaceutical company has obtained the green light from the FDA to launch its phase III study SARA-31 for its potential treatment against sarcopenia. Biophytis obtained similar…
Biophytis obtains FDA authorization to start the SARA-31 phase 3 study in sarcopenia – 09/11/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis obtains a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe
(AOF) – Biophytis SA (a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging) announces today that it has received…
Biophytis has applied to the FDA for authorization to launch the SARA-31 phase 3 study in sarcopenia
By Claude Leguilloux Published on 07/10/2023 at 07:32 (Boursier.com) — Biophytis SA, a clinical-stage biotechnology company specializing…
Biophytis has applied to the FDA for authorization to launch the SARA-31 phase 3 study in sarcopenia – 07/10/2023 at 07:00
Paris (France) and Cambridge (Massachusetts, United States), July 10, 2023 – 7:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company…
Biophytis presents the clinical results of Sarconeos (BIO101) in sarcopenia at the 16th international SCWD congress – 06/19/2023 at 07:00
Paris (France) and Cambridge (Massachusetts, United States), June 19, 2023 – 07:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company…
Biophytis has applied to the EMA for authorization to launch the SARA-31 phase 3 study in sarcopenia – 05/15/2023 at 08:00
Paris, France, Cambridge (Massachusetts, United States), May 15, 2023 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 in the treatment of Sarcopenia at the 15th international SCWD congress – 06/27/2022 at 23:00
Paris, France, Cambridge (Massachusetts, United States), June 27, 2022 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…
Biophytis Presents the Phase 3 Development of Sarconeos (BIO101) in the Treatment of Sarcopenia at the 15th SCWD International Congress
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 in the treatment of Sarcopenia at 15th international SCWD congress Paris, France, Cambridge (Massachusetts, United States), June 27, 2022 –…
Biophytis presents the Sarconeos (BIO101) development program in sarcopenia at the 12th annual International Congress on Frailty and Sarcopenia (ICSFR), in Boston from April 20 to 22, 2022 – 04/19/2022 at 08:00
Paris, France, Cambridge (Massachusetts, United States), April 19, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…